[go: up one dir, main page]

UY30431A1 - Suspensiones acuosas de tmc278 - Google Patents

Suspensiones acuosas de tmc278

Info

Publication number
UY30431A1
UY30431A1 UY30431A UY30431A UY30431A1 UY 30431 A1 UY30431 A1 UY 30431A1 UY 30431 A UY30431 A UY 30431A UY 30431 A UY30431 A UY 30431A UY 30431 A1 UY30431 A1 UY 30431A1
Authority
UY
Uruguay
Prior art keywords
tmc278
pharmaceutical compositions
suspensions
waterproof
waterproof suspensions
Prior art date
Application number
UY30431A
Other languages
English (en)
Inventor
Peter Jozef Maria V Remoortere
Marc Carel Jozef Francois
Laurent Bruno Schueller
Willy Alber Maria Carlo Dries
Derivados De Benzoxazol Estruc
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30431(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of UY30431A1 publication Critical patent/UY30431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion comprende composiciones farmacéuticas para la administracion por inyeccion intramuscular o subcutánea, que comprende micro o nanopartículas del compuesto NNRTI TMC278, suspendido en un portador acuoso farmacéuticamente aceptable, y el uso de dichas composiciones farmacéuticas en el tratamiento y la prevencion de infeccion por VIH.
UY30431A 2006-06-23 2007-06-22 Suspensiones acuosas de tmc278 UY30431A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06115938 2006-06-23

Publications (1)

Publication Number Publication Date
UY30431A1 true UY30431A1 (es) 2008-01-31

Family

ID=38833797

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30431A UY30431A1 (es) 2006-06-23 2007-06-22 Suspensiones acuosas de tmc278

Country Status (33)

Country Link
US (4) US20090176813A1 (es)
EP (2) EP2040671B1 (es)
JP (1) JP5292288B2 (es)
KR (1) KR101406879B1 (es)
CN (1) CN101478950B (es)
AP (1) AP2618A (es)
AR (1) AR061620A1 (es)
AU (1) AU2007262941B2 (es)
BR (2) BRPI0713334B1 (es)
CA (1) CA2654115C (es)
CL (1) CL2007001847A1 (es)
CY (1) CY1120564T1 (es)
DK (2) DK2040671T3 (es)
EA (1) EA021700B1 (es)
ES (2) ES2989051T3 (es)
FI (1) FI3366278T3 (es)
HR (2) HRP20241265T3 (es)
HU (2) HUE038797T2 (es)
IL (1) IL195491A (es)
JO (1) JOP20200160A1 (es)
LT (2) LT2040671T (es)
MX (1) MX2009000158A (es)
NZ (1) NZ573291A (es)
PE (1) PE20080210A1 (es)
PL (2) PL3366278T3 (es)
PT (2) PT3366278T (es)
RS (2) RS65990B1 (es)
SG (1) SG173315A1 (es)
SI (2) SI3366278T1 (es)
TW (1) TWI413521B (es)
UA (1) UA97641C2 (es)
UY (1) UY30431A1 (es)
WO (1) WO2007147882A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP5754005B2 (ja) 2006-01-20 2015-07-22 ヤンセン・アールアンドデイ・アイルランド Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
EP2306980A2 (en) * 2008-06-30 2011-04-13 Tibotec Pharmaceuticals Powders for reconstitution
ES2607107T3 (es) * 2008-12-24 2017-03-29 Janssen Sciences Ireland Uc Dispositivos implantables para tratar el VIH
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
HK1209638A1 (en) 2012-12-14 2016-04-08 Glaxosmithkline Llc Pharmaceutical compositions
BR112017006005A2 (pt) 2014-09-26 2017-12-19 Glaxosmithkline Ip No 2 Ltd composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
US10369129B2 (en) * 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
TWI678203B (zh) * 2016-05-31 2019-12-01 中裕新藥股份有限公司 蛋白酶抑制劑之長效醫藥組合物
CN109475563A (zh) * 2016-05-31 2019-03-15 中裕新药股份有限公司 蛋白酶抑制剂的长效医药组合物
CN110191704A (zh) 2016-10-24 2019-08-30 爱尔兰詹森科学公司 可分散组合物
AU2018298855B2 (en) * 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
MX2023000439A (es) 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
KR20230110763A (ko) * 2020-11-17 2023-07-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 질환 또는 장애의 치료 또는 예방
TW202233192A (zh) 2020-11-17 2022-09-01 愛爾蘭商健生科學愛爾蘭無限公司 Hiv感染之治療或預防
KR20240095514A (ko) 2021-11-17 2024-06-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 용해도 평가
CN119403543A (zh) 2022-04-22 2025-02-07 爱尔兰詹森科学公司 液体组合物
CN119403545A (zh) 2022-04-22 2025-02-07 爱尔兰詹森科学公司 冷冻干燥的组合物
TW202408526A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)
TW202408527A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(二)
CA3268292A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv LONG-ACTING FORMULAS
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2025054693A1 (pt) * 2023-09-14 2025-03-20 Instituto Hercílio Randon Premix funcional de nanopartículas, processo para sua obtenção, processo para modificação de propriedades de materiais e material com propriedades modificadas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102124A (en) * 1976-07-12 1978-07-25 Swager William E Locking clevis or the like
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5046881A (en) * 1991-02-01 1991-09-10 Swager William E Lockable pin and clevis
US5114260A (en) * 1991-05-13 1992-05-19 Hart Judy L Clevis and screw pin type shackle with pin lock
US5272824A (en) * 1993-05-10 1993-12-28 Caterpillar Inc. Tooth assembly with leaf spring retainer
US5423138A (en) * 1994-04-04 1995-06-13 Caterpillar, Inc. Tip to adapter interface
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1214059B1 (en) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US20030166509A1 (en) * 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP5754005B2 (ja) * 2006-01-20 2015-07-22 ヤンセン・アールアンドデイ・アイルランド Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置

Also Published As

Publication number Publication date
HRP20241265T3 (hr) 2024-12-06
US11389447B2 (en) 2022-07-19
CA2654115A1 (en) 2007-12-27
DK2040671T3 (en) 2018-05-07
BRPI0713334A2 (pt) 2012-03-06
HRP20180629T1 (hr) 2018-06-01
RS65990B1 (sr) 2024-10-31
JP5292288B2 (ja) 2013-09-18
HUE038797T2 (hu) 2018-11-28
SI3366278T1 (sl) 2024-12-31
WO2007147882A3 (en) 2008-06-19
ES2989051T3 (es) 2024-11-25
RS57111B1 (sr) 2018-06-29
JOP20200160A1 (ar) 2022-10-30
ES2662068T3 (es) 2018-04-05
PL2040671T3 (pl) 2018-08-31
DK3366278T3 (da) 2024-09-23
MX2009000158A (es) 2009-01-23
TWI413521B (zh) 2013-11-01
IL195491A0 (en) 2009-09-01
KR101406879B1 (ko) 2014-06-13
WO2007147882A2 (en) 2007-12-27
EA021700B1 (ru) 2015-08-31
TW200817008A (en) 2008-04-16
UA97641C2 (en) 2012-03-12
HUE068406T2 (hu) 2024-12-28
EP2040671A2 (en) 2009-04-01
BR122020011487B1 (pt) 2024-02-20
US20150010637A1 (en) 2015-01-08
CN101478950B (zh) 2013-02-06
LT3366278T (lt) 2024-11-11
AR061620A1 (es) 2008-09-10
JP2009541271A (ja) 2009-11-26
EP3366278B1 (en) 2024-08-07
EP3366278A1 (en) 2018-08-29
EA200970047A1 (ru) 2009-04-28
CA2654115C (en) 2015-12-22
LT2040671T (lt) 2018-05-10
CY1120564T1 (el) 2019-07-10
AP2618A (en) 2013-03-18
CN101478950A (zh) 2009-07-08
AP2008004682A0 (en) 2008-12-31
PL3366278T3 (pl) 2024-10-28
CL2007001847A1 (es) 2008-02-08
US20220273653A1 (en) 2022-09-01
KR20090023703A (ko) 2009-03-05
IL195491A (en) 2014-11-30
FI3366278T3 (fi) 2024-09-25
NZ573291A (en) 2011-11-25
PE20080210A1 (es) 2008-04-11
AU2007262941B2 (en) 2013-11-21
PT3366278T (pt) 2024-10-21
SG173315A1 (en) 2011-08-29
BRPI0713334A8 (pt) 2018-01-02
BRPI0713334B1 (pt) 2024-02-20
AU2007262941A1 (en) 2007-12-27
PT2040671T (pt) 2018-03-14
SI2040671T1 (en) 2018-05-31
US20090176813A1 (en) 2009-07-09
US20160089369A1 (en) 2016-03-31
EP2040671B1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
UY30431A1 (es) Suspensiones acuosas de tmc278
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
PH12020500076A1 (en) Long-acting formulations
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
CL2011002494A1 (es) Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih).
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
BR112023000220A2 (pt) Formulações de longa ação
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
UY37488A (es) Novedosas formulaciones de compuestos de beta-lactama sustituidos con amidina sobre la base de ciclodextrinas modificadas y agentes acidificantes, su preparación y uso como composiciones farmacéuticas antimicrobianas
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
AR053571A1 (es) Prevencion de infeccion por vih
CL2008002223A1 (es) Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria.
ECSP10010381A (es) Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave
EA202090287A1 (ru) Составы пролонгированного действия
MX2012003424A (es) Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.
TH2001000208A (th) สารแขวนลอยที่มีเบดาควิลีนที่ออกฤทธิ์ยาวนาน
CL2007001944A1 (es) Compuestos derivados de 5-bencil-pirazol; composicion farmaceutica que comprende a dichos compuestos; y el uso de los compuestos para reforzar la exposicion farmacocinetica de farmacos administrados metabolizados por la enzima cip450

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20191011